Navigating the treatment choices for mycosis fungoides

ONCOLOGY

Volumn 24, Issue 6, 2010, Pages

  Lansigan, Frederick ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; HISTONE DEACETYLASE INHIBITOR; METHOXSALEN;

CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COST OF ILLNESS; DISEASE FREE SURVIVAL; HUMAN; MYCOSIS FUNGOIDES; NOTE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PUVA; SEZARY SYNDROME; TOTAL SKIN ELECTRON THERAPY; TREATMENT OUTCOME;

EID: 77954158154     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Pimpinelli N, Olsen EA, Santucci M, et al: Defining early mycosis fungoides. J Am Acad Dermatol 53:1053-1063, 2005.
2. National comprehensive cancer network (NCCN) practice guidelines in oncology v.2.2009. Available at www.nccn.org.
3. Jones G, Wilson LD, Fox-Goguen L: Total skin electron beam radiotherapy for patients who have mycosis fungoides. Hematol Oncol Clin North Am 17:1421-1434, 2003.
4. Yu JB, Khan AM, Jones GW, et al: Patient perspectives regarding the value of total skin electron beam therapy for cutaneous t-cell lymphoma/mycosis fungoides: A pilot study. Am J Clin Oncol 32:142-144, 2009.
5. Quiros PA, Kacinski BM, Wilson LD: Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with t3 cutaneous t-cell lymphoma treated with total skin electron beam radiation therapy. Cancer 77:1912-1917, 1996.
6. Jones GW, Kacinski BM, Wilson LD, et al: Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organisation for Research and Treatment of Cancer (EORTC) cutaneous lymphoma project group. J Am Acad Dermatol 47:364-370, 2002.